Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has issued an update.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an expected revenue growth of 145% to 155% for the year ending December 31, 2024, driven by strong sales in both domestic and international markets. Despite this growth, the company anticipates an adjusted net loss of RMB435 million to RMB521 million, a significant reduction from the previous year’s loss, due to increased revenue and decreased operating expenses.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology industry, focusing on the development and commercialization of surgical robots. Its primary products include the Toumai Laparoscopic Surgical Robot, the R-ONE Vascular Interventional Surgical Robot, and the SkyWalker Orthopedic Surgical Robot, with a market focus on both domestic and international markets.
YTD Price Performance: 126.60%
Average Trading Volume: 18,121,171
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$21.68B
For a thorough assessment of 2252 stock, go to TipRanks’ Stock Analysis page.